Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Free Cash Flow (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Free Cash Flow for 2 consecutive years, with $23.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 215.35% to $23.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$56.4 million through Dec 2025, up 45.22% year-over-year, with the annual reading at -$56.4 million for FY2025, 45.22% up from the prior year.
  • Free Cash Flow hit $23.1 million in Q4 2025 for Prelude Therapeutics, up from -$19.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $23.1 million in Q4 2025 to a low of -$34.3 million in Q1 2025.